Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 44.20B |
| Revenue (ttm) | 1.80B |
| Net Income (ttm) | -232.90M |
| Shares Out | n/a |
| EPS (ttm) | -1.80 |
| PE Ratio | n/a |
| Forward PE | 74.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,110 |
| Average Volume | 1,458 |
| Open | 450.00 |
| Previous Close | 446.70 |
| Day's Range | 449.03 - 452.00 |
| 52-Week Range | 209.75 - 470.00 |
| Beta | n/a |
| RSI | 70.63 |
| Earnings Date | Aug 7, 2025 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin... [Read more]
Financial Performance
In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.
Financial numbers in USD Financial StatementsNews
Regeneron posts late-stage trial win for myasthenia gravis drug developed with Alnylam
Scenic Enters License and Research Agreement with Alnylam
Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (...
A Closer Look at Alnylam Pharmaceuticals's Options Market Dynamics
Financial giants have made a conspicuous bullish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals (NASDAQ: ALNY) revealed 10 unusual trades. Delving into t...
How Is The Market Feeling About Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals's (NYSE: ALNY) short percent of float has fallen 4.34% since its last report. The company recently reported that it has 3.24 million shares sold short , which is 3.31% of all ...
Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 10 years by 2.77% on an annualized basis producing an average annual return of 14.61%. Currently, Alnylam Pharmaceutic...
Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present new data from its hypertension and...
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord...
This Alnylam Pharmaceuticals Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Reddit, Wingstop, And Generac Are Among Top 10 Large Cap Gainers Last Week (July 28-August 1): Are The Others In Your Portfolio?
These ten large-cap stocks were top performers last week. Are they a part of your portfolio ? Reddit, Inc. (NYSE: RDDT) stock gained 24.7% last week after the company reported better-than-expected se...
Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance
Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) reported upbeat second-quarter earnings and 2025 guidance on Thursday. The company reported a second-quarter 2025 adjusted earnings of 32 cents, down from ...
Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance
Alnylam Pharmaceuticals Inc. ALNY reported upbeat second-quarter earnings and 2025 guidance on Thursday.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call Transcript
Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast
The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) continue to outperform market expectations. Amid a backdrop of growin...
Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast
The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. ALNY continue to outperform market expectations. Amid a backdrop of growing demand fo...
Alnylam: Amvuttra Is Just Getting Started
Alnylam Pharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call Presentation
Alnylam jumps on full year revenue guidance raise
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended J...
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 15 years by 10.3% on an annualized basis producing an average annual return of 22.67%. Currently, Alnylam Pharmaceutic...
Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter end...
Alnylam Pharma Stock Outlook: Is ALNY Topping Out?
Alnylam Pharmaceuticals (NASDAQ: ALNY) is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish structure. ...